Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats

• Published in: The journal of trauma and acute care surgery Vol. 74; no. 2; p. 499
• Main Authors: Bach, 4th, Harold H, Laporte, Heather M, Wong, Yee M, Gamelli, Richard L, Majetschak, Matthias
• Format: Journal Article
• Language: English
• Published: United States 01.02.2013
• Subjects: Adenosine Triphosphate - analysis; Adenosine Triphosphate - physiology; Animals; Blotting, Western; Boronic Acids - therapeutic use; Bortezomib; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Proteasome Endopeptidase Complex - drug effects; Proteasome Endopeptidase Complex - physiology; Proteasome Inhibitors - therapeutic use; Pyrazines - therapeutic use; Rats; Rats, Inbred Lew; Shock, Hemorrhagic - drug therapy; Shock, Hemorrhagic - mortality; Shock, Hemorrhagic - physiopathology
• ISSN: 2163-0763
• DOI: 10.1097/TA.0b013e31827d5db2

Several lines of evidence suggest that proteasomes, the major nonlysosomal proteases in eukaryotes, are involved in the pathophysiology of various disease processes, including ischemia-reperfusion injury and trauma. Recently, we demonstrated that 26S proteasome activity is negatively regulated by adenosine triphosphate (ATP) and that proteasome activation during ischemia contributes to myocardial injury. The regulation of tissue proteasome activity by ATP and the potential of proteasomes as drug targets during hemorrhagic shock, however, are unknown. Thus, we evaluated the regulation of tissue proteasome peptidase activity and the effects of the proteasome inhibitor bortezomib in rat models of hemorrhagic shock. Series 1 includes animals (n = 20) hemorrhaged to a mean arterial blood pressure of 30 mm Hg for up to 45 minutes. Series 2 includes animals hemorrhaged to a mean arterial blood pressure of 30 mm Hg for 30 minutes, followed by bortezomib (0.4 mg/kg) or vehicle administration (n =5 per group) and fluid resuscitation until 75 minutes. Series 3 includes animals that underwent 40% blood volume hemorrhage, followed by 2% blood volume hemorrhage every 15 minutes until death. Bortezomib (0.4 mg/kg) or vehicle were administered 15 minutes after the onset of hemorrhage (n = 6-7 per group). Vital signs were continuously monitored. The heart, lung, and pectoral muscle were analyzed for proteasome peptidase activities and levels of ATP, ubiquitin-protein conjugates, and cytokines (tumor necrosis factor α, interleukin 6, and interleukin 10). In Series 1, proteasome peptidase activities in tissue extracts increased proportional to the decrease in tissue ATP concentrations during hemorrhagic shock. Activation of proteasome peptidase activity with decreases of the ATP assay concentration was also detectable in normal tissue extracts. In Series 2, systemic administration of bortezomib inhibited tissue proteasome activities but did not affect the physiologic response. In Series 3, bortezomib inhibited tissue proteasome activities, increased endogenous ubiquitin-protein conjugates, and prolonged survival time from treatment from 48.5 minutes in the control group to 85 minutes (p = 0.0012). Bortezomib treatment did not affect tissue cytokine levels. Proteasome activation contributes to the pathophysiology of severe hemorrhagic shock. Pharmacologic inhibition of the proteasome may provide a survival advantage during lethal hemorrhagic shock.